Kennedy Disease - 17 Studies Found Active, not recruiting : The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer : Prostate Cancer : 2013-02-08 : Drug: ARN-509 Drug: LHRH Agonist Recruiting : Phase II Trial of Enzalutamide for CRPC With Correlative Assessment of Androgen Receptor Signaling : Prostate Cancer : 2013-09-04 : Drug: Enzalutamide Administration: 160 mg orally once dail Terminated : GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer : Estrogen Receptor Negative Breast Cancer Human Epidermal Growth Factor 2 Negative Carcinoma : 2013-07-25 : Drug: cisplatin Recruiting : A Phase I Study of a DNA Vaccine Encoding Androgen Receptor Ligand-Binding Domain (AR LBD) +/-GMCSF : Prostate Cancer : 2015-03-27 : Biological: pTVG-AR Given ID Recruiting : Efficacy and Safety of GTx-024 in Patients With Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC) : Triple Negative Breast Cancer : 2015-02-10 : Drug: GTx-024 GTx-024 softgel capsules will be administered once-daily to a total dose of 18 mg Suspended : Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer : Estrogen Receptor Negative Estrogen Receptor Positive HER2 : 2015-05-21 : Other: Biomarker Analysis Corr Recruiting : Phase IIB Neoadjuvant Enzalutamide (ZT) Plus Taxol for Androgen Receptor (AR)-Positive Triple-Negative Breast Cancer (AR+ TNBC) : Breast Cancer : 2016-02-12 : Drug: Enzalutamide 120 mg by m <<< Previous
